Bronze
At Dxome, we aim to provide the best products to improve the quality of healthcare. Complexity of human biology requires development of advanced technologies to detect minute amount of information that heavily influences the quality of life of individuals. We provide variety of early detection panels and monitoring after treatment through the detection of circulating tumor DNA (ctDNA) using Next-Generation Sequencing (NGS) technology. In addition, we possess screening panels and health check-up panels of hereditary cancer and disorders. Together with hereditary and ctDNA panels, Dxome strives to enables early treatment and prolong monitoring of patients, which ultimately leads to higher survival rates. In order to face the challenges of human biology, Dxome strive to keep the highest standards of quality in products and provide innovative solutions based on cutting-edge technologies to ultimately aim for Personalized Medicine to each individual.
Dxome’s products utilizes our own revolutionary technology that provide high sensitivity and accuracy while being user-friendly and cost-effective. With the large collection of genomic data obtained by high-throughput sequencing, underlying bioinformatic workflows, and highly accurate detections panels, we provide clinically actionable insights for personalized treatment of hereditary and somatic cancers. Dxome is ready to launch Pan100 and TMB500 panels for detection of somatic cancers through liquid biopsy using NGS platform, in which crucial genes for various cancers.
